SKIN.SW up 9.85% to CHF35.70 on SIX 10 Feb 2026: high-volume move suggests demand

First sentence hook: SKIN.SW stock jumped 9.85% to CHF35.70 on the SIX intraday session on 10 Feb 2026, trading heavier than normal with 2,756 shares changing hands. The move puts Cassiopea S.p.A. (SKIN.SW) firmly among today’s high-volume movers and follows a gap open at CHF32.00. Investors should note the intraday range CHF32.00–CHF36.00, a 50-day average of CHF34.37, and a 200-day average of CHF37.22 when weighing momentum against longer-term resistance.

Intraday price and volume snapshot for SKIN.SW stock

SKIN.SW stock is trading at CHF35.70, up CHF3.20 or 9.85% from the previous close of CHF32.50. The session opened at CHF32.00 and hit an intraday high of CHF36.00. Volume is 2,756 versus an average of 1,818, giving a relative volume of 1.52, which confirms genuine intraday interest.

The short-term picture shows the price above the 50-day average (CHF34.37) but below the 200-day average (CHF37.22). Year-to-date volatility and the intraday range suggest traders are testing demand around current levels.

Fundamentals and valuation metrics for SKIN.SW stock

Cassiopea S.p.A. operates in Healthcare / Biotechnology with known assets such as Winlevi and Breezula. The TTM EPS is -1.27, producing a negative P/E of -28.13 and a price-to-book ratio of 26.04. The company shows a current ratio of 1.98 and cash per share CHF0.25, indicating short-term liquidity is intact despite negative earnings.

The balance-sheet metrics point to low leverage with a debt-to-equity near 0.00x, but operating cash flow per share is -0.95 and free cash flow per share is -0.96, showing continued cash burn consistent with a clinical-stage biopharma profile. These figures matter for valuation and near-term capital planning.

Clinical pipeline, catalysts and sector context for SKIN.SW stock

Cassiopea’s portfolio centers on dermatology candidates: Winlevi (acne), Breezula (androgenic alopecia, Phase II), and CB-06 series (topical antibiotics). Clinical readouts or regulatory news remain primary catalysts for material moves in SKIN.SW stock.

Healthcare sector performance has been positive recently, with the Swiss healthcare group showing modest gains YTD. Sector strength can amplify stock moves when company-specific news appears. For company details see the issuer site Cassiopea and for market context see the SIX exchange overview SIX Swiss Exchange.

Technical outlook and Meyka stock grade for SKIN.SW stock

Technically, SKIN.SW cleared the 50-day average and met resistance near the 200-day average at CHF37.22. Support sits near today’s open at CHF32.00 and the 1-year low CHF25.70. Momentum indicators remain mixed with above-average intraday volume confirming interest but limited conviction above the 200-day average.

Meyka AI rates SKIN.SW with a score out of 100: 62.62 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and are not financial advice.

Trading strategy and risk points for high-volume SKIN.SW stock moves

For intraday traders: consider scaling positions with tight risk limits given SKIN.SW’s current day range CHF32.00–CHF36.00 and relative volume 1.52. A break and hold above the 200-day average CHF37.22 could open a short-term target near CHF42.00–CHF49.00.

Risks include continuing cash burn, negative EPS (-1.27), wide P/B (26.04) and binary clinical readouts. Use stop-losses below today’s support and size positions to account for potential wide swings in this biotech stock.

Valuation outlook and price target scenarios for SKIN.SW stock

Meyka AI’s scenario view: a conservative base-case values SKIN.SW at CHF31.00, a base-case at CHF38.00, and a bullish clinical-success scenario at CHF49.00. These levels reflect different clinical and commercial outcomes and assume no near-term dilutive financing.

Meyka AI’s forecast model projects CHF42.50 over 12 months versus the current price CHF35.70, implying an upside of 19.05%. Forecasts are model-based projections and not guarantees.

Final Thoughts

SKIN.SW stock moved sharply intraday on 10 Feb 2026, rising to CHF35.70 on volume 2,756, a clear high-volume mover on the SIX. The stock sits above its 50-day average but below the 200-day average, leaving a defined technical pivot at CHF37.22. Fundamentals show a clinical-stage biotech with negative EPS (-1.27) and cash burn, offset by low leverage and pipeline assets that can trigger binary moves.

Meyka AI’s forecast model projects CHF42.50 in 12 months, an implied upside of 19.05% from CHF35.70. Our proprietary grade is B (62.62) with a HOLD suggestion; the grade considers sector comparison, growth metrics, and analyst signals. Traders focused on high-volume intraday moves can trade momentum but should respect technical resistance and clinical risk. For company facts and filings, see Cassiopea’s site and the SIX exchange; for real-time metrics visit our SKIN.SW stock page on Meyka AI for live updates. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.